PPCB vs PRME

Propanc Biopharma, Inc. vs Prime Medicine, Inc. — Valuation Comparison 2026

PPCB

Biotechnology
Propanc Biopharma, Inc.
Quality
3.7
out of 10
Value Trap
36
LOW
Price
$1.70
Last close
Models
6/13
Active
VS

PRME

Biotechnology
Prime Medicine, Inc.
Quality
5.1
out of 10
Value Trap
26
LOW
Price
$3.40
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType PPCB Fair ValuePPCB Upside PRME Fair ValuePRME Upside
Bayesian DCF Intrinsic $0.50 -70.8% $0.85 -75.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.82 -75.9%
Dynamic NAV Asset-Based $6.64 +290.6% $0.76 -77.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PPCB vs PRME — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PPCB vs PRME — Which Stock Is More Undervalued?

PRME scores higher with a 5.1/10 quality rating vs PPCB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Propanc Biopharma, Inc. (PPCB) and Prime Medicine, Inc. (PRME) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PPCB currently trades at $1.70 with a QOC of 3.7/10, while PRME trades at $3.40 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).